ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print July 12, 2006, 10.1183/09031936.06.00125705
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiang, C-Y.
Right arrow Articles by Lin, T-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiang, C-Y.
Right arrow Articles by Lin, T-P.
Eur Respir J 2006; 28:980-985
Copyright ©ERS Journals Ltd 2006

Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study

C-Y. Chiang1, D. A. Enarson1, M-C. Yu2, K-J. Bai2, R-M. Huang3, C-J. Hsu4, J. Suo4 and T-P. Lin4

1 International Union Against Tuberculosis and Lung Disease, Paris, France. 2 Taipei Medical University-Municipal Wan Fang Hospital, Taipei, and 3 Chest Hospital, Dept of Health, Tainan, Taiwan, and 4 National Tuberculosis Association, Taipei, China.

CORRESPONDENCE: D. A. Enarson, International Union Against Tuberculosis and Lung Disease, 68 Boulevard Saint-Michel 75006, Paris, France. Fax: 33 886225771501. E-mail: denarson{at}iuatld.org

Keywords: Death, follow-up, multidrug resistant, relapse, tuberculosis

Received: October 27, 2005
Accepted June 23, 2006

A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan.

All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992–1996 were enrolled and their outcome over the subsequent 6 yrs was determined.

A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (CI) 0.03–0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% CI 0.31–0.82).

In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
D. H. Kim, H. J. Kim, S.-K. Park, S.-J. Kong, Y. S. Kim, T.-H. Kim, E. K. Kim, K. M. Lee, S. S. Lee, J. S. Park, et al.
Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis
Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1075 - 1082.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.